Active Filter(s):
Details:
Through the acquisition, Shorla gains Jylamvo, an oncology and autoimmune drug and easy-to-administer, sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation, for the US market.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Jylamvo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Shorla Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023